Clinical characteristics of included trials.

(CSV)

Characteristics of included studies.

BackgroundIt remains unknown which is the optimal first-line treatment regimen for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung...

Objective: To assess the cost-effectiveness of pembrolizumab monotherapy compared with standard chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in...

Results of direct comparisons.

(XLSX)

Demographics and baseline characteristics for opioid groups by quartiles.

VATS procedures for non-small cell lung cancer performed by type of the number of port.

Univariate and multivariate Cox proportional hazard analysis for mortality in EGFR positive lung adenocarcinoma subjects.

Frequency of EGFR-TKI resistant or co-exiting* mutations.

Summary of second-line treatment patterns.

Lung cancer remains one of the most prominent public health challenges, accounting for the highest incidence and mortality among all human cancers. While pulmonary invasive...

Main characteristics of the patient population and assessment of generalizability.

BackgroundThe goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of...

Clinical characteristics of both groups.

Analysis of relationships between vimentin and clinicopathological variables in NSCLC.

The baseline characteristics in patients based on PD-L1 expression level.

Estimate of overall survival considering the clinical variables and plasma level of IL-6.

Demographic and clinical characteristics of patients by receipt of one or more molecular testsa (yes/no) in Japan, Korea, Taiwan, and Brazil.